SEC Form 10-K filed by SRAX Inc.

Westlake Village, CA, May 08, 2024 (GLOBE NEWSWIRE) -- SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, announced today it has entered into a definitive merger agreement with DNA Holdings Venture Inc. pursuant to which the shareholders of DNA will become the majority owners of SRAX's outstanding common stock as more fully described below upon the closing of the merger. DNA has been a long term investor in SRAX and currently owns approximately 35% of the company.  DNA is  a Web3 investment company which provides both advisory services and invests in Web3 infrastructure. The company was foun

Los Angeles, March 05, 2024 (GLOBE NEWSWIRE) -- Los Angeles, [5 March 2024] - SRAX Inc. (OTC:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through its SaaS platform Sequire, today announced it has selected XDEFI as its Web3 wallet partner. XDEFI is a pioneering multichain cryptocurrency wallet. The partnership will enable SRAX's network of active equity investors to access decentralized applications and assets spanning 200+ blockchains, seamlessly and securely. In addition, SRAX clients who download the wallet will be eligible for airdrops in $XDEFI tokens and many future token airdrops.  In 2023, over $5 billion was given away through

Westlake Village, Dec. 18, 2023 (GLOBE NEWSWIRE) -- Dear Shareholders, As I write to you today, I do so with a sense of deep reflection on the year that has passed. It's been a period that tested our resilience. I want to express my sincere regret for the concerns and frustrations you may have experienced as a result of our stock price. Addressing Our Challenges Head-On Our delisting from the NASDAQ market was a moment for serious introspection. Looking back, there were areas where we should have been more proactive, especially as it relates to our accounting team's leadership and the complexities of the accounting for our business.  Bringing in new experts was a turning point for th

Dawson James initiated coverage of SRAX with a rating of Buy and set a new price target of $10.00

B. Riley reiterated coverage of SRAX with a rating of Buy and set a new price target of $7.50 from $4.50 previously

Ladenburg Thalmann initiated coverage of SRAX with a rating of Buy and set a new price target of $7.00

4 - SRAX, Inc. (0001538217) (Issuer)

4 - SRAX, Inc. (0001538217) (Issuer)

4 - SRAX, Inc. (0001538217) (Issuer)

3 - SRAX, Inc. (0001538217) (Issuer)

10-Q - SRAX, Inc. (0001538217) (Filer)

10-K - SRAX, Inc. (0001538217) (Filer)

8-K - SRAX, Inc. (0001538217) (Filer)

For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

For Immediate Release: March 22, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA issued an emergency use authorization for Pemgarda (pemivibart) for the pre-exposure prophylaxis (prevention) of COVID-19 in certain adults and adolescents (12 years of age and older weighing at least 40 kilograms [about 88 pounds]).  Pemgarda is

For Immediate Release: November 09, 2023 Today, the U.S. Food and Drug Administration approved Adzynma, the first recombinant (genetically engineered) protein product indicated for prophylactic (preventive) or on demand enzyme replacement therapy (ERT) in adult and pediatric patients with congenital thrombotic thrombocytopenic purpura (cTTP), a rare and life-threatening blood clotting disorder. “The FDA remains

For Immediate Release: June 07, 2024 Today, the U.S. Food and Drug Administration is providing an at-a-glance summary of news from around the agency:  Today, the FDA announced that it has advised the manufacturers of the licensed and authorized COVID-19 vaccines that the COVID-19 vaccines (2024-2025 Formula) for use in the United States should be monovalent (single strain) JN.1 vaccines to more closely match cu

Los Angeles, California--(Newsfile Corp. - March 20, 2023) - SRAX, Inc. (NASDAQ:SRAX), a leading financial technology company, has announced the appointment of Alan Urban as the CFO of SRAX. Mr. Urban has over 30 years of experience in corporate finance and accounting. He has previously served in numerous senior management positions, most notably as Chief Financial Officer for ten years at Research Solutions, a provider of SaaS solutions for life science organizations. Mr. Urban also serves on the Board of Directors of GT Biopharma."We are excited to have Alan step into this very important role at SRAX. We believe his 30 years of expertise will be instrumental in getting our accounting t

LAS VEGAS, NEVADA , April 14, 2022 (GLOBE NEWSWIRE) -- Publicly traded Nevada blockchain, decentralized finance (DeFi), and cryptocurrency-focused investment company ICOA Inc. (OTC:ICOA) announced this week that they have entered a $500,000 deal with SRAX (NASDAQ:SRAX) to maximize and accelerate its communications for interested investors, shareholders, and supporters. Through SRAX, a publicly traded company offering premier operating system tools for publicly traded companies, ICOA will have the ability to further reach its community through sophisticated solutions to assist it in maintaining, communicating, and expanding its shareholder base. With Sequire, a product of SRAX, IC

Los Angeles, California--(Newsfile Corp. - March 9, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that provides data and insights to publicly traded companies through its SaaS platform Sequire, would like to reassure its investors that the company's core business remains strong despite the recent delisting notice from NASDAQ. The delisting was caused by a late filing, and the company is actively working to regain compliance as soon as possible.We are pleased to report that SRAX has added over 25 new customers in the first quarter of 2023, indicating the strength of our business and the value we provide to our clients. We remain confident that this momentum will continue, a

Purchase brings pre-eminent small-cap platform to the Freedom family Freedom U.S. Markets, LLC, a wholly-owned subsidiary of Freedom Holding Corp. (NASDAQ:FRHC), announced today that it has completed the acquisition of LD Micro from SRAX, Inc. (NASDAQ:SRAX). The total consideration of $8.3 million includes $4 million in cash and FRHC common stock valued at $4.3 million. LD Micro offers two premier small-cap conferences annually, the Invitational: June 6-8 (Los Angeles) and the Main Event: October 3-5 (Los Angeles), which hosts over 200 companies and 1,000 investors. For the past 15 years, the LD Micro conferences have showcased the next big names in the small-cap world to investors and i

Los Angeles, California--(Newsfile Corp. - February 6, 2023) - SRAX, Inc. (NASDAQ:SRAX), a financial technology company that unlocks data and insights for publicly traded companies through Sequire, its SaaS platform, has acquired the assets of DNA Holdings, LLC.DNA specializes in helping private technology companies with positioning, marketing, and strategy. The emphasis on private companies provides the expertise for SRAX to accelerate the entrance into the cap table management for private companies. The private cap table management market is anticipated to grow to over $1 Billion by 2030. This market is a natural extension of SRAX's current Sequire Platform that helps public companies m

SC 13G/A - SRAX, Inc. (0001538217) (Subject)

SC 13G/A - SRAX, Inc. (0001538217) (Subject)

SC 13G/A - SRAX, Inc. (0001538217) (Subject)